{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:26:46Z","timestamp":1791286006103,"version":"4.1.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1,27]]},"DOI":"10.1097\/tp.0b013e318193886e","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T03:25:50Z","timestamp":1232421950000},"page":"157-163","source":"Crossref","is-referenced-by-count":115,"title":["The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy"],"prefix":"10.1097","volume":"87","author":[{"given":"Anthony P.","family":"Monaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210129","first-page":"147","article-title":"Occurrence of cancers in immunosuppressed organ transplant recipients.","author":"Penn","year":"1998","journal-title":"Clin Transpl"},{"key":"R2-1-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States.","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"R3-1-20210129","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MNH.0b013e3282f06bba","article-title":"Cancer after renal transplantation.","volume":"16","author":"Vasudev","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R4-1-20210129","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1097\/01.tp.0000186382.81130.ba","article-title":"Malignancy after transplantation.","volume":"80","author":"Buell","year":"2005","journal-title":"Transplantation"},{"issue":"suppl 1","key":"R5-1-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ndt\/gfm085","article-title":"Malignancies in renal transplantation: An unmet medical need.","volume":"22","author":"Dantal","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R6-1-20210129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","article-title":"Post transplant de novo malignancies in renal transplant recipients: The past and present.","volume":"19","author":"Kauffman","year":"2006","journal-title":"Transplant Int"},{"key":"R7-1-20210129","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation.","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"R8-1-20210129","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients.","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transplant"},{"key":"R9-1-20210129","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: A collaborative transplant study report.","volume":"4","author":"Opeltz","year":"2004","journal-title":"Am J Transplant"},{"key":"R10-1-20210129","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00042307-200303000-00004","article-title":"Tumors after kidney transplantation.","volume":"13","author":"Lutz","year":"2003","journal-title":"Curr Opin Urol"},{"key":"R11-1-20210129","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/00007890-200011150-00012","article-title":"Long-term follow-up after liver transplantation for alcoholic liver disease under Tacrolimus.","volume":"70","author":"Jain","year":"2000","journal-title":"Transplantation"},{"key":"R12-1-20210129","first-page":"1113","article-title":"Causes of late failure after heart transplantation: A ten-year survey.","volume":"16","author":"Gallo","year":"1997","journal-title":"J Heart Lung Transplant"},{"key":"R13-1-20210129","first-page":"1383","article-title":"De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.","volume":"25","author":"Sheil","year":"1993","journal-title":"Transplant Proc"},{"key":"R14-1-20210129","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1097\/01.TP.0000120181.89206.54","article-title":"Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.","volume":"79","author":"Guba","year":"2004","journal-title":"Transplantation"},{"key":"R15-1-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trre.2005.01.001","article-title":"Rapamycin and tumor growth: Mechanisms behind it anti-cancer activity.","volume":"19","author":"Koehl","year":"2005","journal-title":"Transplant Rev"},{"key":"R16-1-20210129","first-page":"3895","article-title":"Rapamycin inhibits constitutive p7R56K phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells.","volume":"56","author":"Seufferlein","year":"1996","journal-title":"Cancer Res"},{"key":"R17-1-20210129","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0041-1345(02)02899-3","article-title":"Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which provokes cell growth.","volume":"34","author":"Schumacher","year":"2002","journal-title":"Transplant Proc"},{"key":"R18-1-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor.","volume":"8","author":"Guba","year":"2002","journal-title":"Nature Med"},{"key":"R19-1-20210129","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: Unlinking immunosuppression from anti-tumor efficacy.","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"R20-1-20210129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","article-title":"Rapamycin is an effective inhibitor of human renal cancer metastasis.","volume":"63","author":"Luan","year":"2003","journal-title":"Kidney Int"},{"key":"R21-1-20210129","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1078-0432.CCR-0629-3","article-title":"Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer.","volume":"10","author":"Boffa","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R22-1-20210129","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","article-title":"Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from post transplant lymphoproliferative disorder at allograft protecting doses.","volume":"75","author":"Majewski","year":"2003","journal-title":"Transplantation"},{"key":"R23-1-20210129","first-page":"4472","article-title":"Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein-Barr virus B-cell lymphomasl.","volume":"63","author":"Nepomuceno","year":"2003","journal-title":"Cancer Res"},{"key":"R24-1-20210129","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/00007890-200405150-00002","article-title":"Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.","volume":"77","author":"Koehl","year":"2004","journal-title":"Transplantation"},{"key":"R25-1-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism.","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"R26-1-20210129","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-\u03b2, expression and promotes tumor progression.","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"R27-1-20210129","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1097\/01.tp.0000186912.23630.85","article-title":"mTOR inhibition and its effect on cancer in transplantation.","volume":"80","author":"Andrassy","year":"2005","journal-title":"Transplantation"},{"key":"R28-1-20210129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/01.tp.0000280548.99241.c4","article-title":"Cancer and transplantation intersect at the mammalian target of rapamycin.","volume":"84","author":"MacDonald","year":"2007","journal-title":"Transplantation"},{"key":"R30-1-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two year incidence of malignancy in Sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"R31-1-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R32-1-20210129","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.TP.0000173770.42403.F7","article-title":"Low incidence of malignancy among sirolimus\/cyclosporine treated renal transplant recipients.","volume":"80","author":"Kahan","year":"2005","journal-title":"Transplantation"},{"key":"R33-1-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.transproceed.2006.01.019","article-title":"Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.","volume":"38","author":"Yakupoglie","year":"2005","journal-title":"Transplant Proc"},{"key":"R34-1-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/00007890-199910270-00024","article-title":"For the FK506 kidney transplant study group. Cytomegalo virus infection and post-transplant lymphoproliferative disease in renal transplant recipients: Results of the U.S. multicenter FK506 kidney transplant study group.","volume":"68","author":"Pirsch","year":"1999","journal-title":"Transplantation"},{"key":"R35-1-20210129","first-page":"353","article-title":"A multicenter analysis of discharge immunosuppression and post-transplant malignancy. [abstract 868].","volume":"1","author":"Cherikh","year":"2001","journal-title":"Am J Transplant"},{"key":"R36-1-20210129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target of rapamycin inhibitors is associated with reduced incidence of de novo malignancies.","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"R37-1-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1535-6108(03)00002-3","article-title":"Initation of angiogenic Kaposi's sarcoma lesions.","volume":"3","author":"Hayward","year":"2003","journal-title":"Cancer Cell"},{"key":"R38-1-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00007890-199608270-00007","article-title":"Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence.","volume":"62","author":"Doutrelepont","year":"1996","journal-title":"Transplantation"},{"key":"R39-1-20210129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/01.TP.0000115344.18025.0B","article-title":"Conversion to sirolimus: A successful treatment for post-transplantation Kaposi's sarcoma.","volume":"77","author":"Campistol","year":"2004","journal-title":"Transplantation"},{"key":"R40-1-20210129","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1016\/j.transproceed.2005.10.076","article-title":"Efficacy of conversion to sirolimus in post transplant Kaposi's sarcoma.","volume":"37","author":"Gutierrez-Dalmain","year":"2005","journal-title":"Transplant Proc"},{"key":"R41-1-20210129","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.transproceed.2004.12.172","article-title":"Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.","volume":"37","author":"Zmonarski","year":"2005","journal-title":"Transplant Proc"},{"key":"R42-1-20210129","first-page":"366","article-title":"Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.","volume":"3","author":"Mohsin","year":"2005","journal-title":"Exp Clin Transplant"},{"key":"R43-1-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10157-007-0470-y","article-title":"Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal transplant recipient.","volume":"11","author":"Gheith","year":"2007","journal-title":"Clin Exp Nephrol"},{"key":"R44-1-20210129","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1742-1241.2006.00815.x","article-title":"Regression of posttransplant Kaposi's sarcoma using sirolimus.","volume":"60","author":"Kolhe","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R45-1-20210129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal transplant patients.","volume":"352","author":"Stallone","year":"2005","journal-title":"N Eng J Med"},{"key":"R46-1-20210129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMc058158","article-title":"Kaposi's sarcoma after renal transplantation. [letter to the editor].","volume":"353","author":"Edey","year":"2005","journal-title":"N Engl J Med"},{"key":"R47-1-20210129","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1600-6143.2006.01412.x","article-title":"Sirolimus conversion for patients with post transplant Kaposi's sarcoma.","volume":"6","author":"Lebbe","year":"2006","journal-title":"Am J Transplant"},{"key":"R48-1-20210129","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/01.tp.0000203322.99037.d2","article-title":"No effect of sirolimus for Kaposi's sarcoma in renal transplant recipient.","volume":"81","author":"Graf","year":"2006","journal-title":"Transplantation"},{"key":"R49-1-20210129","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi's sarcoma in renal-transplant recipients [reply to letter to the editor].","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"R50-1-20210129","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/01.tp.0000203322.99037.d2","article-title":"No effect of Sirolimus for Kaposi's sarcoma in a renal transplant recipient [letter to the editor].","volume":"81","author":"Descoeudres","year":"2006","journal-title":"Transplantation"},{"key":"R51-1-20210129","first-page":"726","article-title":"Sirolimus for Kaposis sarcoma.","volume":"6","author":"Wasywich","year":"25","journal-title":"J Heart Lung Transplant"},{"key":"R52-1-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-3062.2007.00239.x","article-title":"Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod.","volume":"10","author":"Babel","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"R53-1-20210129","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.intimp.2006.09.018","article-title":"Recurrence of Kaposi's sarcoma after increased exposure to sirolimus.","volume":"6","author":"Boratynska","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R54-1-20210129","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1432-2277.2006.00435.x","article-title":"No recurrence of Kaposi's sarcoma in a case of renal retransplantation under calcineurin inhibitor free immunosuppressive regimen: First report [letter to the editor].","volume":"20","author":"Segolini","year":"2007","journal-title":"Transpl Int"},{"key":"R55-1-20210129","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1053\/j.ajkd.2006.11.037","article-title":"Monitoring antitumor efficacy of rapamycin in Kaposi's sarcoma.","volume":"49","author":"DiPaolo","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R56-1-20210129","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/01.tp.0000250767.67472.58","article-title":"Conversion to sirolimus in renal transplant recipients with skin cancer [letter to the editor].","volume":"82","author":"Tessmer","year":"2006","journal-title":"Transplantation"},{"key":"R57-1-20210129","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.transproceed.2006.08.016","article-title":"Conversion from calcineurin inhibitors to everlimus in kidney transplant recipients with malignant neoplasia.","volume":"38","author":"Fernandez","year":"2006","journal-title":"Transplant Proc"},{"issue":"suppl 3","key":"R58-1-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfl300","article-title":"Everolimus in clinical practice\u2014Renal transplantation.","volume":"21","author":"Pascual","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 1","key":"R59-1-20210129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ndt\/gfm086","article-title":"Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.","volume":"22","author":"de Fyter","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R60-1-20210129","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1600-6143.2006.01648.x","article-title":"Switching from tarolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome.","volume":"7","author":"Levi","year":"2007","journal-title":"Am J Transplant"},{"key":"R61-1-20210129","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/0002-9343(91)90637-D","article-title":"Association of sebaceous gland tumors and internal malignancy: The Muir-Torre syndrome.","volume":"90","author":"Cohen","year":"1991","journal-title":"Am J Med"},{"key":"R62-1-20210129","first-page":"1149","article-title":"Transplantation of the liver.","author":"Buell"},{"key":"R63-1-20210129","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transpl"},{"key":"R64-1-20210129","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/lt.20283","article-title":"Hepatocellular cancer, transplantation, and sirolimus [editorial].","volume":"10","author":"Wall","year":"2004","journal-title":"Liver Transpl"},{"key":"R65-1-20210129","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis.","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R66-1-20210129","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/hep.510270616","article-title":"Survival after liver transplantation for small hepato-cellular carcinoma: The tumor-node-metastases classification does not have prognostic power.","volume":"27","author":"Llovet","year":"1998","journal-title":"Hepatology"},{"key":"R67-1-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1072-7515(03)00140-6","article-title":"Surgical treatment of hepatocellular cancer in the era of hepatic transplantation.","volume":"196","author":"DeCarlis","year":"2003","journal-title":"J Am Coll Surg"},{"key":"R68-1-20210129","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/jlts.2002.34892","article-title":"Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TMN criteria.","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transpl"},{"key":"R69-1-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/jlts.2001.25458","article-title":"Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma.","volume":"7","author":"Herrero","year":"2001","journal-title":"Liver Transpl"},{"key":"R70-1-20210129","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.TP.0000154913.88193.FF","article-title":"Complete remission of post-transplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil.","volume":"77","author":"Elsharkawi","year":"2005","journal-title":"Transplantation"},{"key":"R71-1-20210129","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.transproceed.2005.03.013","article-title":"Successful use of sirolimus in a patient with bulky ovarian metastases of hepatocellular carcinoma after liver transplantation.","volume":"37","author":"Stippel","year":"2005","journal-title":"Transplant Proc"},{"key":"R72-1-20210129","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects.","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"R73-1-20210129","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3748\/wjg.v12.i19.3114","article-title":"Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.","volume":"12","author":"Zhou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R74-1-20210129","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1016\/j.transproceed.2006.10.070","article-title":"Characteristics of neoplasm occurrence and the therapeutic effect of sirolimus in South Chinese kidney transplant recipients.","volume":"38","author":"Wang","year":"2006","journal-title":"Transplant Proc"},{"key":"R75-1-20210129","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1432-2277.2007.00505.x","article-title":"Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: A single center experience.","volume":"20","author":"Zimmerman","year":"2007","journal-title":"Transpl Int"},{"key":"R76-1-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.tp.0000252780.42104.95","article-title":"Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.","volume":"83","author":"Sieghart","year":"2007","journal-title":"Transplantation"},{"key":"R77-1-20210129","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplant patients.","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"key":"R78-1-20210129","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/ndt\/gfh884","article-title":"Resolution of renal allograft-associated post transplant lymphoproliferative disorder with introduction of sirolimus.","volume":"20","author":"Zaltzman","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R79-1-20210129","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.transproceed.2007.03.092","article-title":"Complete regression of cutaneous B cell lymphoma in a renal transplant patient after conversion from cyclosporine to sirolimus.","volume":"39","author":"Mohsin","year":"2007","journal-title":"Transplant Proc"},{"key":"R80-1-20210129","doi-asserted-by":"crossref","first-page":"E67","DOI":"10.1053\/j.ajkd.2006.01.029","article-title":"Sirolimus\u2014Induced remission of posttransplantation lymphoproliferative disorder.","volume":"47","author":"Cullis","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R81-1-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1399-3046.2004.00156.x","article-title":"Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma.","volume":"8","author":"Jimenez-Rivera","year":"2004","journal-title":"Pediatr Transplant"},{"key":"R82-1-20210129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1432-2277.2003.tb00287.x","article-title":"Rituximab in association with rapamycin for posttransplant lymphoproliferative disease treatment.","volume":"16","author":"Garcia","year":"2003","journal-title":"Transpl Int"},{"key":"R83-1-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1399-3046.2005.00253.x","article-title":"Rapid reponse to rituximab in a pediatric liver transplant recipient with posttransplant lymphoproliferative disease and maintenance with sirolimus monotherapy.","volume":"9","author":"Al Akash","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R84-1-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D30B43T7TG","article-title":"Posttransplant Epstein-Barr virus related lymphoproliferative disorder with a primary cutaneous presentation.","volume":"13","author":"Snavely","year":"2007","journal-title":"Dermatol Online J"},{"key":"R85-1-20210129","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.tripleo.2006.01.014","article-title":"Monomorphic Epstein-Barr virus (EBV)-associated large B cell posttransplant lymphoproliferative disorder presenting as a tongue ulcer in a pancreatic transplant patient.","volume":"102","author":"Bruce","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"R86-1-20210129","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-06-028092","article-title":"Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.","volume":"109","author":"Sin","year":"2007","journal-title":"Blood"},{"key":"R87-1-20210129","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1600-6143.2007.02110.x","article-title":"Human Herpesvirus-8(HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin.","volume":"8","author":"Boulanger","year":"2008","journal-title":"Am J Transplant"},{"key":"R88-1-20210129","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.transproceed.2006.08.063","article-title":"Conversion to sirolimus in renal transplant patients with tumors.","volume":"38","author":"Sanchez-Fructosso","year":"2006","journal-title":"Transplant Proc"},{"key":"R89-1-20210129","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.tp.0000280549.93403.dd","article-title":"Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.","volume":"84","author":"Gomez-Camarero","year":"2007","journal-title":"Transplantation"},{"key":"R90-1-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.transproceed.2007.05.046","article-title":"Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: Case reports.","volume":"39","author":"Iaria","year":"2007","journal-title":"Transplant Proc"},{"key":"R91-1-20210129","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.transproceed.2007.06.055","article-title":"Conversion to sirolimus in post transplant renal neoplasms.","volume":"39","author":"Lopez","year":"2007","journal-title":"Transplant Proc"},{"key":"R92-1-20210129","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.transproceed.2007.08.078","article-title":"Anticancer effect of sirolimus in renal allograft recipients.","volume":"39","author":"Boratynska","year":"2007","journal-title":"Transplant Proc"},{"key":"R93-1-20210129","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.transproceed.2005.03.142","article-title":"Successful management of recurrent Epstein-Barr virus associated leiomyosarcoma after cardiac transplantation.","volume":"37","author":"Bonatti","year":"2005","journal-title":"Transplant Proc"},{"key":"R94-1-20210129","doi-asserted-by":"crossref","first-page":"L955","DOI":"10.1016\/S1470-2045(06)70943-3","article-title":"Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumor.","volume":"7","author":"Toh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"R95-1-20210129","doi-asserted-by":"crossref","first-page":"i36","DOI":"10.1093\/ndt\/gfm090","article-title":"Use of proliferation signal inhibitors in management of posttransplant malignancies\u2014Clinical guidance.","volume":"22","author":"Campistol","year":"2007","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200901270-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:30:45Z","timestamp":1786037445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200901270-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,27]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e318193886e","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1,27]]}}}